PHASE I STUDY OF SMS 201 995 PA LAR (NSC 685403)+ & TAMOXIFEN IN PA

SMS 201 995 PA LAR (NSC 685403) 的第一阶段研究

• 批准号: 6263531
• 负责人: DOUGLAS HAWKINS
• 金额: $ 0.39万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6263531
• 关键词: clinical research; clinical trial phase I; combination chemotherapy; human subject; human therapy evaluation; insulinlike growth factor; neoplasm /cancer chemotherapy; osteosarcoma; peptide hormone analog; somatostatin; tamoxifen

Recent investigations suggest that Insulin like growth factor (IGF 1) may play a role in the pathobiology of osteosarcoma. Somatostatin directly inhibits the release of growth hormone, thereby indirectly reducing the level of circulating IGF 1. We propose to administer the long acting somatostatin analog, SMS 201-995 pa LAR, alone and in combination with tamoxifen in patients with osteosarcoma. The degree of suppression of both circulating IGF 1 and growth hormone will be determined.

最近的研究表明，胰岛素样生长因子（igf1）可能在骨肉瘤的病理生物学中发挥作用。生长抑素直接抑制生长激素的释放，从而间接降低循环中的igf1水平。我们建议在骨肉瘤患者中单独或联合他莫昔芬使用长效生长抑素类似物SMS 201-995 pa LAR。循环igf1和生长激素的抑制程度将被确定。